Caixin Securities
Search documents
业绩超预期,海外市场表现亮眼
Caixin Securities· 2024-04-15 16:00
2024 年 04 月 15 日 涨跌幅比较 公司点评 中际联合(605305.SH) | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | 预测指标 | | 2022A | | 2023A | | | | 2024E | | 2025E | 2026E | | 主营收入 ( 亿元 ) | | 7.99 | | | 11.05 | | | 14.00 | | 18.00 | 23.00 | | 净利润 ( 亿元 ) | | 1.55 | | | 2.07 | | | 2.61 | | 3.46 | 4.62 | | 每股收益(元) | | 1.02 | | | 1.36 | | | 1.72 | | 2.28 | 3.04 | | 每股净资产(元 ...
业绩稳步增长,持续市场开拓
Caixin Securities· 2024-04-15 16:00
证券研究报告 公司点评 科达利(002850.SZ) 电力设备| 电池 业绩稳步增长, 持续市场开拓 2024年 04月 15日 预测指标 2022A 2023A 2024E 2025E 2026E 评级 买入 主营收入(亿元) 86.54 105 .11 131.73 160.12 191.61 归母净利润(亿元) 9.01 12.01 12.50 15.42 18.44 评级变动 维持 每股收益(元) 3.34 4.45 4.63 5.71 6.83 交易数据 每股净资产(元) 20.46 38.12 42.49 47.89 54.35 当前价格(元) 87.72 P/E 26.28 19.72 18.95 15.36 12.84 52周价格区间(元) 58.03-146.33 P/B 4.29 2.30 2.06 1.83 1.61 总市值(百万) 23684.94 资料来源:iFinD,财信证券 流通市值(百万) 16860.28 总股本(万股) 27000.70 投资要点: 流通股(万股) 19220.60 事件:2024年 4月 12日,公司发布 2023年年报,公司全年实现营收 105.11 ...
全面解读2024年《国九条》:加强监管、防范风险,推动高质量发展
Caixin Securities· 2024-04-14 16:00
证券研究报告 此报告仅供内部客户参考 请务必阅读正文之后的免责条款部分 券基金机构服务实体经济、居民财富增值、防范化解风险等社会性功 能。同时,《意见》提出,要积极培育良好的行业文化和投资文化,完 善与经营绩效、业务性质、贡献水平、合规风控、社会文化相适应的 证券基金行业薪酬管理制度;坚决纠治拜金主义、奢靡享乐、急功近 利、"炫富"等不良风气。党的坚强领导、健康的文化、合理的薪酬制 度,是证券基金机构可持续发展的重要基石,这将为证券基金机构专 注、专业,发挥服务实体经济、助力居民财富增值以及防范化解风险 等功能提供有力组织与思想保障。 投资建议:2024 年《国九条》在加强监管、防范风险基础上,推动资 本市场高质量发展,一系列措施将优化、重塑 A 股市场生态。同时, 大力推动中长期资金入市,重点做好科技金融、绿色金融、普惠金融、 养老金融、数字金融五篇大文章,建议关注上述政策支持方向。 此报告仅供内部客户参考 -2- 请务必阅读正文之后的免责条款部分 一、事件 《意见》提出,要以强监管、防风险、促高质量发展为主线,以完善资本市场基础制 度为重点,更好发挥资本市场功能作用,推进金融强国建设,服务中国式现代化大局 ...
公司业绩持续回升,产能进入投产高峰
Caixin Securities· 2024-04-14 16:00
Investment Rating - The report maintains an "Accumulate" rating for the company [2][7]. Core Views - The company achieved total revenue of 234.87 billion yuan in 2023, representing a year-on-year growth of 5.62%. The net profit attributable to shareholders was 6.91 billion yuan, a significant increase of 197.83% year-on-year [5][8]. - The company is experiencing a recovery in profitability, with the aromatics industry chain showing good profit recovery and polyester fibers demonstrating a positive trend. The sales volume of PTA increased by 33.99% year-on-year, with a gross margin improvement of 5.13% [5][6]. - The company is actively expanding its production capacity in high-end chemical new materials, with several key projects expected to come online in the first half of 2024 [6][7]. Financial Forecasts - The company is projected to achieve revenues of 262.37 billion yuan, 276.48 billion yuan, and 285.32 billion yuan for the years 2024, 2025, and 2026, respectively. The net profit attributable to shareholders is expected to be 9.90 billion yuan, 11.47 billion yuan, and 13.34 billion yuan for the same years [5][8]. - Earnings per share (EPS) are forecasted to be 1.41 yuan, 1.63 yuan, and 1.90 yuan for 2024, 2025, and 2026, respectively [7][8]. - The report suggests a price-to-book (P/B) ratio of 2.0-2.2 for 2024, corresponding to a stock price range of 19.42-21.36 yuan [7].
财信证券晨会纪要
Caixin Securities· 2024-04-14 16:00
2024 年 04 月 15 日 晨会聚焦 一、财信研究观点 A 股市场概览 【市场策略】风险偏好回落,短期适度控制仓位 二、重要财经资讯 【宏观经济】3 月金融统计数据报告出炉 三、行业及公司动态 【行业动态】《推动消费品以旧换新行动方案》发布,打造家电换新链条, 培养家电换新意识 【公司跟踪】锡业股份(000960.SZ):2023 年归母净利润同比增长 4.61% 【公司跟踪】振华股份(603067.SH):2023 年归母净利润同比减少 11.07% 四、湖南经济动态 【湘股动态】千金药业(600479.SH):2023 年实现扣非归母净利润 3.04 亿元,同比增长 8.94% 偏好回落,短期适度控制仓位 【宏观策略类】全面解读 2024 年《国九条》:加强监管、防范风险, 推动高质量发展 【宏观策略类】A 股研究启示录五:小市值风格的理论与实践研究 此报告仅供内部客户参考 -2- 请务必阅读正文之后的免责条款部分 何晨 分析师 执业证书编号:S0530513080001 hechen@hnchasing.com 周艺晗 研究助理 zhouyihan96@hnchasing.com 【债券研究】债券 ...
汽车行业月度点评:3月汽车产销量同比稳定增长,两部门调整汽车贷款有关政策
Caixin Securities· 2024-04-14 16:00
证券研究报告 行业月度点评 汽车 3 月汽车产销量同比稳定增长,两部门调整汽车贷 款有关政策 2024年04月11日 2022A 2023E 2024E 重点股票 评级 EPS(元) PE(倍) EPS(元) PE(倍) EPS(元) PE(倍) 评级 同步大市 长安汽车 0.79 22.18 0.98 17.88 1.06 16.23 买入 评级变动: 维持 银轮股份 0.48 36.90 0.74 23.93 0.90 19.70 买入 均胜电子 0.28 59.89 0.77 21.78 1.00 16.77 买入 行业涨跌幅比较 新坐标 1.15 17.87 1.30 15.81 1.48 13.89 买入 汽车 沪深300 资料来源:iFinD(2024-4-10收盘价),财信证券 18% 8% 投资要点: -2% 市场行情回顾:2024年 3月 11日至 2024年4月10日,沪深300指 -12% 数涨跌幅为-2.36%。本月申万一级行业涨跌幅中位数为-1.34%,汽车行 -22% 业(申万一级)涨跌幅为+2.09%,高于沪深 300指数 4.45pcts,处于板 2023-04 2023- ...
财信证券晨会纪要
Caixin Securities· 2024-04-11 16:00
2024 年 03 月 18 日 | --- | --- | --- | --- | --- | |------------|-------|---------|-------|--------| | | | | | | | 市场数据 | | | | | | 指数名称 | | 收盘 | | 涨跌 % | | 上证指数 | | 3054.64 | | 0.54 | | 深证成指 | | 9612.75 | | 0.60 | | 创业板指 | | 1884.09 | | 0.06 | | 科创 50 | | 808.67 | | 0.47 | | 北证 50 | | 892.73 | | 3.42 | | 沪深 300 | | 3569.99 | | 0.22 | | --- | --- | --- | --- | --- | |------------|-----------------|--------------------|-----------|-----------| | 类别 | 总市值 ( 亿元 ) | 流通市 值 ( 亿元 ) | 市盈率 PE | 市净率 PB | | 上证指数 | 56717 ...
大类资产跟踪周报:美国降息节奏延后,A股延续震荡
Caixin Securities· 2024-04-10 16:00
Core Insights - The report highlights a V-shaped rebound in the A-share market driven by strong consumption data during the Qingming holiday, with domestic tourist numbers recovering to 111.5% of 2019 levels and revenue reaching 112.7% [14][5] - The report indicates that the U.S. non-farm payrolls data significantly exceeded market expectations, leading to a delay in the anticipated interest rate cuts by the Federal Reserve [14][5] Weekly Asset Tracking - The report notes that commodities performed well, particularly precious metals and non-ferrous metals, while oil prices experienced fluctuations due to geopolitical tensions and OPEC+ production cuts [15][35] - The report suggests that the bond market remains stable with a slight downward trend in interest rates, influenced by the central bank's continued accommodative stance [15][30] Stock Market Analysis - A-shares showed slight gains across major indices, with small-cap indices outperforming large-cap indices, and growth styles leading over value styles [21][24] - The report emphasizes the importance of sectors such as automotive, home appliances, and telecommunications, which are expected to benefit from marginal improvements in fundamentals [14][7] Bond Market Overview - The report indicates that the central bank's liquidity management has resulted in a stable bond market, with the 10-year government bond yield slightly declining to 2.28% [30][15] - The report also notes that the bond market is expected to maintain a strong trend, although there may be potential adjustment pressures on medium to long-term yields [15][30] Commodity Market Insights - The report highlights that precious metals, particularly gold and silver, have shown strong performance, with gold prices remaining robust amid geopolitical uncertainties [35][15] - The report anticipates that oil prices will continue to operate at high levels due to tight supply and sustained demand [15][35] High-Frequency Data Tracking - The report mentions a slight decline in the AH share premium, which stood at 11.23%, indicating a favorable valuation compared to historical averages [39][15] - The report also notes that the risk premium for the entire A-share market remains above its historical median, suggesting continued investor interest [39][15]
医疗器械行业月度点评:北京发布医药创新支持文件,看好创新药械产业链
Caixin Securities· 2024-04-10 16:00
证券研究报告 行业月度点评 医疗器械 北京发布医药创新支持文件,看好创新药械产业 链 2024年 04月08日 2022A 2023E 2024E 重点股票 评级 EPS(元) PE(倍) EPS(元) PE(倍) EPS(元) PE(倍) 评级 领先大市 迈瑞医疗 7.92 34.88 9.76 28.30 11.59 23.84 买入 评级变动: 维持 心脉医疗 4.31 41.54 5.95 30.09 7.85 22.81 买入 福瑞股份 0.37 127.30 0.38 123.95 0.65 72.46 增持 行业涨跌幅比较 维力医疗 0.57 18.84 0.62 17.32 0.82 13.10 增持 医疗器械 沪深300 资料来源:iFinD,财信证券 3% 投资要点: -7% 行情回顾:上周医药生物(申万)板块涨幅为1.91%,在申万 32个一 -17% 级行业中排名第24位,医疗器械(申万)板块涨幅为 1.21%,在 6个 -27% 申万医药二级子行业中排名第 4位,跑输医药生物(申万)0.70百分 2023-04 2023-07 2023-10 2024-01 点,跑赢沪深 300 ...
医药生物行业月度报告:创新支持政策频出,重点关注创新药及其产业链
Caixin Securities· 2024-04-10 16:00
行业研究报告 行业月度报告 医药生物 创新支持政策频出,重点关注创新药及其产业链 2024年 04月09日 2022A 2023E 2024E 重点股票 评级 EPS(元) PE(倍) EPS(元) PE(倍) EPS(元) PE(倍) 评级 领先大市 药明康德 3.00 15.62 3.28 14.33 3.27 14.33 买入 评级变动: 维持 凯莱英 8.94 9.28 6.14 13.50 3.29 25.21 买入 泰格医药 2.30 24.75 2.32 24.52 2.80 20.30 买入 行业涨跌幅比较 九典制药 0.78 45.66 1.13 31.49 1.41 25.23 买入 益丰药房 1.25 33.14 1.33 31.14 1.66 25.04 买入 医药生物 沪深300 9% 健之佳 2.82 16.63 3.08 15.21 3.94 11.90 买入 -1% 金域医学 5.87 8.66 1.74 29.19 2.81 18.11 买入 -11% 资料来源:Wind,财信证券 -21% -31% 投资要点: 2023-04 2023-07 2023-10 2024-01 ...